Theralase Technologies Inc. (TSXV:TLT), a biotech stock, jumped after providing an update on its Phase Ib Non-Muscle Invasive Bladder Cancer clinical study
Sean Mason | May 17, 2018 | SmallCapPower
Promising clinical study results produced a healthy gain for a biotech stock Thursday. Here’s some small stocks making big moves on Thursday, May 17, 2018 (as of 4 pm EST):
Theralase Technologies Inc. (TSXV:TLT), a biotech stock, surged 58% to $0.315 on Thursday after providing an update on the Phase Ib Non-Muscle Invasive Bladder Cancer clinical study currently in progress, in which the Company said Patient Number Six’s 90-day clinical cystoscopy assessment to rule out recurrent NMIBC has now been completed and the patient has demonstrated no clinical evidence or presence of disease.
As well, shares of ATS Automation Tooling Systems Inc. (TSX:ATA) gained 11% to $19.25 as the automation solutions provider said its fiscal 2018 revenue rose 10% to $1.12 billion, while earnings per share for the year was $0.50 compared with $0.38 during fiscal 2017.
International Zeolite Corp. (TSXV:IZ), meanwhile, reported that it has submitted its first order for 400 tonnes of natural zeolite from Cuba. The Company added that it has now has increased capabilities to delivery and supply zeolite markets around the world with Cuba’s support and expertise. International Zeolite stock moved up 30% to $0.37 following the announcement.
Finally, AnalytixInsight Inc. (TSXV:ALY) shares continued to move higher Thursday, up 3% to $0.495. Shares of the Artificial Intelligence company surged 33% on Wednesday after announcing that it has entered into a distribution agreement with Thomson Reuters, whereby Thomson Reuters will distribute financial research reports created by AnalytixInsight’s artificial intelligence platform to customers on its financial desktop applications Eikon and Thomson One.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: